Solara Active Pharma Sciences Ltd
NSE:SOLARA

Watchlist Manager
Solara Active Pharma Sciences Ltd Logo
Solara Active Pharma Sciences Ltd
NSE:SOLARA
Watchlist
Price: 488.9 INR -4.01% Market Closed
Market Cap: 23.5B INR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one SOLARA stock under the Base Case scenario is 643.8 INR. Compared to the current market price of 488.9 INR, Solara Active Pharma Sciences Ltd is Undervalued by 24%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SOLARA Relative Value
Base Case
643.8 INR
Undervaluation 24%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.8
P/S
P/S
Price to Sales
1.8
vs History
58
vs Industry
51
Median 3Y
1.6
Median 5Y
2.1
Industry
2.4
Forward
1.5
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-13.3
Median 5Y
-7.1
Industry
20.5
Forward
21.7
More Details
19.3
P/OCF
P/OCF
Price to OCF
19.3
vs History
34
vs Industry
21
Median 3Y
11.4
Median 5Y
12.3
Industry
15.4
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
0
Median 3Y
-35.7
Median 5Y
-35.6
Industry
22.8
More Details
2.2
P/B
P/B
Price to Book Value
2.2
vs History
53
vs Industry
32
Median 3Y
1.4
Median 5Y
2.3
Industry
1.9
More Details
1.9
EV/S
EV/S
Enterprise Value to Sales
1.9
vs History
69
vs Industry
50
Median 3Y
2
Median 5Y
2.4
Industry
2.5
Forward
1.6
More Details
4
EV/GP
EV/GP
Enterprise Value to Gross Profit
4
vs History
74
vs Industry
45
Median 3Y
4.8
Median 5Y
5.6
Industry
4.9
More Details
14.1
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
14.1
vs History
57
vs Industry
24
Median 3Y
13.6
Median 5Y
15.1
Industry
12.4
Forward
8.7
More Details
34.4
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
34.4
vs History
23
vs Industry
12
Median 3Y
-13.5
Median 5Y
23
Industry
15.5
Forward
15
More Details
20
EV/OCF
EV/OCF
Enterprise Value to OCF
20
vs History
36
vs Industry
20
Median 3Y
12.6
Median 5Y
13.6
Industry
14
More Details
27.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
27.9
vs History
47
vs Industry
16
Median 3Y
31.1
Median 5Y
27
Industry
17.9
More Details
1.2
EV/IC
EV/IC
Enterprise Value to IC
1.2
vs History
58
vs Industry
47
Median 3Y
1
Median 5Y
1.4
Industry
1.8
More Details

Multiples Across Competitors

SOLARA Competitors Multiples
Solara Active Pharma Sciences Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Solara Active Pharma Sciences Ltd
NSE:SOLARA
23.5B INR 1.8 -9.3 14.1 34.4
US
Eli Lilly and Co
NYSE:LLY
669.1B USD 15 64.3 36.9 41.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
356B USD 4 25.3 11.9 15.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK 6.3 18.3 11.9 13.8
CH
Roche Holding AG
SIX:ROG
193.7B CHF 3.3 16.8 9.5 11.3
CH
Novartis AG
SIX:NOVN
171.4B CHF 3.9 16.7 10.2 13.2
UK
AstraZeneca PLC
LSE:AZN
155.3B GBP 3.7 28.2 125.4 191.5
US
Merck & Co Inc
NYSE:MRK
195.2B USD 3 11.5 7.8 9.3
IE
Endo International PLC
LSE:0Y5F
162.4B USD 70 -55.5 259.5 650.8
US
Pfizer Inc
NYSE:PFE
122.1B USD 1.9 15.2 7.6 10.9
P/E Multiple
Earnings Growth PEG
IN
Solara Active Pharma Sciences Ltd
NSE:SOLARA
Average P/E: 24.6
Negative Multiple: -9.3 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
64.3
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
25.3
26%
1
DK
Novo Nordisk A/S
CSE:NOVO B
18.3
19%
1
CH
Roche Holding AG
SIX:ROG
16.8
16%
1
CH
Novartis AG
SIX:NOVN
16.7
16%
1
UK
AstraZeneca PLC
LSE:AZN
28.2
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.5
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -55.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
15.2
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Solara Active Pharma Sciences Ltd
NSE:SOLARA
Average EV/EBITDA: 394.7
14.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.9
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
11.9
7%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11.9
15%
0.8
CH
Roche Holding AG
SIX:ROG
9.5
8%
1.2
CH
Novartis AG
SIX:NOVN
10.2
5%
2
UK
AstraZeneca PLC
LSE:AZN
125.4
9%
13.9
US
Merck & Co Inc
NYSE:MRK
7.8
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
259.5
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
3%
2.5
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Solara Active Pharma Sciences Ltd
NSE:SOLARA
Average EV/EBIT: 1 699.6
34.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
41.8
33%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
15.6
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
13.8
16%
0.9
CH
Roche Holding AG
SIX:ROG
11.3
9%
1.3
CH
Novartis AG
SIX:NOVN
13.2
8%
1.7
UK
AstraZeneca PLC
LSE:AZN
191.5
21%
9.1
US
Merck & Co Inc
NYSE:MRK
9.3
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
650.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.9
10%
1.1

See Also

Summary
SOLARA intrinsic value, competitors valuation, and company profile.
DCF Valuation
SOLARA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
SOLARA stock valuation using valuation multiples.
Wall Street Estimates
SOLARA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
SOLARA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 245,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.